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Phenocopy of a heterozygous 
carrier of X‑linked retinitis 
pigmentosa due to mosaicism 
for a RHO variant
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Marieke De Bruyne3, Toon Rosseel3, Stijn Van de Sompele3,4, Elfride De Baere2,3,4* & 
Bart P. Leroy1,2,3,5,6*
We describe both phenotype and pathogenesis in two male siblings with typical retinitis pigmentosa 
(RP) and the potentially X‑linked RP (XLRP) carrier phenotype in their mother. Two affected sons, 
two unaffected daughters, and their mother underwent detailed ophthalmological assessments 
including Goldmann perimetry, color vision testing, multimodal imaging and ISCEV‑standard 
electroretinography. Genetic testing consisted of targeted next‑generation sequencing (NGS) of 
known XLRP genes and whole exome sequencing (WES) of known inherited retinal disease genes 
(RetNet‑WES). Variant validation and segregation analysis were performed by Sanger sequencing. 
The mutational load of the RHO variant in the mother was assessed in DNA from leucocytes, buccal 
cells and hair follicles using targeted NGS. Both affected sons showed signs of classical RP, while 
the mother displayed patches of hyperautofluorescence on blue light autofluorescence imaging and 
regional, intraretinal, spicular pigmentation, reminiscent of a carrier phenotype of XLRP. XLRP testing 
was negative. RetNet‑WES testing revealed RHO variant c.404G > C p.(Arg135Pro) in a mosaic state 
(21% of the reads) in the mother and in a heterozygous state in both sons. Targeted NGQSS of the 
RHO variant in different maternal tissues showed a mutation load between 25.06% and 41.72%. We 
report for the first time that somatic mosaicism of RHO variant c.404G > C p.(Arg135Pro) mimics the 
phenotype of a female carrier of XLRP, in combination with heterozygosity for the variant in the two 
affected sons.
Retinitis Pigmentosa (RP) is a group of progressive inherited retinal diseases (IRDs) characterized by rod-
degeneration preceding cone-degeneration. RP has a worldwide prevalence of 1:4000, making it a leading cause 
of visual  disability1. In keeping with the differential involvement of the photoreceptor systems, patients with RP 
usually first display symptoms of night blindness, followed by progressive loss of vision in the midperipheral 
visual fields. In the later stages of the disease, the cone-rich center is affected as well, with concomitant decline 
of visual acuity. The age of onset varies  greatly1–3.
RP can be inherited in an autosomal dominant (ADRP, 15–25% of cases), autosomal recessive (ARRP, 5–20%), 
or X-linked fashion (XLRP, 5–15%). The remainder are mostly simplex cases (30–55%)4,5. ADRP patients gener-
ally show a milder phenotype, with longer preservation of central vision. The recessive and X-linked forms tend 
to be more severe in progression. A special entity are the female carriers of X-linked RP. Talib et al. recently com-
pared a cohort of 125 heterozygous carriers of X-linked retinitis pigmentosa GTPase regulator (RPGR) mutations 
and described a wide spectrum of phenotypes, ranging from no symptoms to a severe phenotype. Overall, 23% 
of heterozygous carriers displayed a complete phenotype, although usually milder than in affected hemizygous 
 males6. Mutations in RPGR account for most cases of XLRP, while mutations in the RP2 and OFD1 genes are 
less  frequent7.
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Here, we report the clinical and genetic characterization of the first case of a mosaic carrier of a dominant 
RHO c.404G > C p.(Arg135Pro) variant, showing clinical signs suggestive for XLRP, and her two sons, heterozy-
gous for the variant, with typical signs of RP.
Material and methods
The proband (III.1), his siblings (III.2, III.3, III.4) and his mother (II.1) underwent a full clinical and genetic 
work-up (Fig. 1).
This study was conducted following the tenets of the Declaration of Helsinki and ethical approval was given 
by the ethics committee at Ghent University Hospital/Ghent University. All patients were enrolled in a clinical 
context. Verbal and written informed consent for study participation was obtained from all patients.
Clinical study. A detailed review of the medical records was performed and symptoms were registered. 
Best-corrected visual acuity measurements, slit-lamp biomicroscopy, fundoscopy, Goldmann perimetry with 
visual field areas determined with the V4e, I4e and I2e targets and color vision testing with Ishihara, Hardy-
Rand-Rittler pseudo-isochromatic plates and the Farnsworth Panel D-15 arrangement test were conducted. 
Multimodal imaging included spectral-domain optical coherence tomography (OCT) (Heidelberg Spectralis, 
Heidelberg Engineering, Heidelberg, Germany), white light fundus pictures (Topcon Medical Systems, Tokyo, 
Japan) and fundus autofluorescence-imaging (FAF) using both short wavelength (blue) and near-infrared light 
(Heidelberg HRA2, Heidelberg Engineering, Heidelberg, Germany). Full-field flash electroretinograms were 
recorded according to the standards as described by the International Society for Clinical Electrophysiology of 
Vision standard (ISCEV)8.
Genetic and genomic study. Peripheral blood samples were collected in EDTA tubes and DNA was 
extracted using the QiAmp, Gentra Puregene Cell kit (Qiagen, Antwerp, Belgium) or the ReliaPrep Large-Vol-
ume HT gDNA Isolation System (Promega, Leiden, the Netherlands) according to the manufacturer’s protocol. 
DNA from buccal mucosa and hair follicles was extracted using NaOH and Tris-HCl. The coding and exon–
intron regions of the RPGR (ENST00000378505), RP2 (ENST00000218340) genes, as well as the deep intronic 
OFD1 IVS9 + 706A > G mutation were tested in the proband (III.1) using targeted next-generation sequenc-
ing (NGS). PCR-enrichment of all coding exons and flanking intron sequences was followed by sequencing by 
synthesis (MiSeq, Illumina). A variant of class 3, 4 or 5 was confirmed by Sanger sequencing. Individuals II.1 
and III.1 underwent whole exome sequencing on a HiSeq 3000 (Illumina) after exome enrichment using the 
SureSelect Human All Exon V6 kit (Agilent). Read alignment and variant calling were performed using the CLC 
Genomics Workbench (v7.5.4). Variants were annotated and filtered using in-house software. Variants were 
scored heterozygous or homozygous in case of a variant allele frequency of 20–69% and minimum 70% respec-
tively. A selection of 265 RetNet genes was assessed (gene panel version v5). Variants were assessed on the basis 
of predictions done in Alamut HT/Alamut Batch. (Likely) pathogenic variants were confirmed using Sanger 
sequencing. Nucleotide numbering was done following HGVS-guidelines (http://www.hgvs.org) with nucleo-
tide ‘A’ of the ATG as ‘c.1’. Classification of variants was based on the ACMG guidelines with  adaptations9–12. 
Targeted testing of the RHO variant (II.1, III.1, III.2, III.3, III.4) was performed using Sanger sequencing of exon 
2 (Ref Seq, ENST00000296271). An estimation of the mutation load in II.1 was performed on DNA extracted 
Figure 1.  Pedigree of the family and segregation analysis of the RHO variant. Filled symbol: affected individual. 
Striped symbol: mildly affected female, mimicking carriership of XLRP. M/ + : heterozygous RHO variant 
c.404G > C p.(Arg135Pro). + / + : homozygous wild type. mM/ + : mosaicism for c.404G > C p.(Arg135Pro).
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from blood using bidirectional Sanger sequencing of RHO exon 2 and data analysis using SeqPilot (JSI Medical 
Systems GmbH, Germany). To assess the mutation load in multiple tissues (blood, buccal mucosa and hair fol-
licles), targeted deep sequencing was performed using a flexible targeted next-generation protocol, consisting 
of singleplex-PCR, followed bij NexteraXT library preparation and sequencing on a MiSeq instrument as previ-
ously  described13. Variants were filtered with a minimum allele frequency threshold of 1%. The sequencing depth 
varied from 147 to 17,523 reads (after removal of duplicate reads and overlapping paired-end reads).
Results
Phenotypic characteristics. Individual III.1. The elder son was first examined at the age of 21. He had 
nyctalopia at the age of six years. His general medical history was unremarkable. Best-corrected visual acu-
ity (BCVA) was 20/20 in both eyes. Slit-lamp examination was unremarkable. Fundoscopy showed attenuated 
retinal blood vessels, peripheral outer retinal atrophy and RPE alterations together with spicular intraretinal 
pigment migrations. OCT imaging confirmed perimacular outer retinal atrophy and demonstrated bilateral 
cystoid macular  edema14. On blue-light autofluorescence imaging (BAF) a mottled aspect of a mostly hypo-
autofluorescent retinal periphery, with a small hyperautofluorescent ring surrounding the central macula was 
seen (Fig. 2). Near-infrared autofluorescence imaging showed a fairly homogeneous hyperautofluorescent cen-
tral macular area with diffuse hypo-autofluorescence around it. Both eyes were affected equally on fundoscopy 
and autofluorescence imaging (Fig. 2). Goldmann visual fields showed a normal central sensitivity and a loss 
of sensitivity in both the pericentral and midperipheral regions, however with normal peripheral limits. Color 
vision testing was normal. ISCEV-standard full-field flash ERG showed absent scotopic rod-specific responses, 
significantly decreased combined rod-cone responses to intense flashes and significantly decreased and delayed 
photopic cone-specific responses (Fig. 3). A clinical diagnosis of RP was made based on all of the findings above.
Individual III.2. The younger son was first seen at the age of 19. He complained of nyctalopia and photophobia 
since he was a toddler. His general medical history revealed an attention deficit disorder (ADD). His BCVA was 
20/20 in both eyes. Slit-lamp examination was unremarkable. Fundoscopy showed spicular intraretinal pigment 
Figure 2.  Fundus imaging. (A) Fundus pictures of both eyes of individual III.1 (age 28): note RPE alterations 
in retinal midperiphery and periphery. Spicular intraretinal pigment migrations in the periphery. (B) Fundus 
pictures of both eyes of individual II.1 (age 52): Midperipheral RPE alterations and pigment migrations, more 
pronounced in, but not exclusive to nasal midperiphery. (C) Blue light autofluorescent imaging of both eyes 
of individual III.1 (age 28): mottled hypo-autofluorescent periphery, with small hyper-autofluorescent ring 
around the macula, with a second hyperfluorescent ring around temporal vascular arcades. (D) Blue light 
autofluorescent imaging of both eyes of individual II.1 (age 52): note mosaic pattern of hyperfluorescent areas, 
some around the vasculature.
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migration and RPE alterations in the retinal periphery. Autofluorescence imaging with blue light revealed a 
mottled hypo-autofluorescent retinal periphery. Around the macula, a small, hyperautofluorescent ring with a 
hypo-autofluorescent zone around it was observed. Goldmann visual fields showed decreased pericentral sen-
sitivity with normal peripheral limits. Color vision testing was normal. ISCEV-standard full-field flash ERG 
revealed considerably reduced and delayed scotopic rod-specific and photopic cone-specific all responses were 
decreased and delayed (data not shown). A diagnosis of RP was made based on the above findings. Imaging and 
functional testing showed individual III.2 was less severely affected than his elder brother (III.1). Both eyes were 
affected equally.
Sisters III.3 and III.4. Both had a completely normal extensive ophthalmological examination. The RHO 
c.404G > C p.(Arg135Pro) variant was not found in both individuals.
Individual II.1. Individual II.1, the mother of the proband was first examined thoroughly at the age of 45. She 
had undergone radial keratotomy to correct moderate myopia in both eyes in her twenties. BCVA was 20/20 in 
both eyes. Slit-lamp biomicroscopy showed scars of the radial keratotomies in both eyes, but was otherwise unre-
markable. Only when questioned specifically about symptoms of RP, she reported difficulty navigating at night, 
as well as mild photophobia. Fundoscopy showed bilateral, but only very limited sectors of intraretinal pigment 
migration and RPE alterations, especially nasally to the optic disc. Blue light autofluorescence imaging revealed 
patches of hyperautofluorescence randomly distributed and interspersed by normal areas throughout the retina 
in both eyes. The left eye was more affected than the right eye. (Fig. 2). This patchy distribution is a typical 
finding seen in female carriers of X-linked RP, due to the female X-inactivation, also known as  lyonization15,16. 
Goldmann visual fields were normal except for a very mild decrease in sensitivity in the midperipheral fields. 
Figure 3.  ISCEV standard full-field flash electroretinogram (ERG). (Top traces) Right eye (RE) of proband 
(III.1) at age 29. Scotopic ERG: complete absence of rod specific response to a dim white flash (0.01 cd.s/m2); 
residual response to slightly higher intensity red flash (0,3 cd.s/m2); responses to high intensity flashes (3.0 cd.s/
m2 and 10.0 cd.s/m2) show significant reduction of amplitudes and major delay in peak times. Photopic ERG: 
response to a transient, high-intensity flash (3.0 cd.s/m2) also shows significant reduction in amplitudes and 
a delay of responses. This is confirmed by response to a 30 Hz high intensity (3.0 cd.s/m2) flicker stimulus. 
(Middle traces) RE of the mother of the proband (II.1) at age 50. Scotopic rod specific ERG: reduction of 
amplitude of rod specific response to a dim white flash (0.01 cd.s/m2) to about two thirds of normal; response to 
slightly higher intensity red flash (0.3 cd.s/m2) shows conserved response of cone-specific part (b1), with similar 
decrease to two thirds of normal amplitude of rod-specific response (b2); responses to high-intensity flashes 
(3.0 cd.s/m2 and 10.0 cd.s/m2) show similar reduction to two thirds of normal for both a- and b-waves with 
only minor delay of responses. Photopic ERG: response to a transient high-intensity flash (3.0 cd.s/m2) shows 
mild delay of b-wave (right column top trace) and mild delay to a 30 Hz high intensity (3.0 cd.s/m2) flicker 
stimulus (right column bottom trace). (Bottom traces) Normal reference traces of a healthy control subject.
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ISCEV-standard full field-flash ERG revealed a reduction of the amplitudes of scotopic, rod-specific and mixed 
rod-cone responses as well as photopic cone-specific responses to 70% of normal values, with a mild delay of the 
peak times for all (Fig. 3). Based on the findings in II.1 and her sons, and on phenotypes in this family, as well as 
the pedigree, an X-linked RP was suspected.
Genomic profiling. Given the suspicion of XLRP, genetic testing for XLRP was requested for individual 
III.1. Panel testing for RPGR (including ORF15), RP2, and a deep intronic OFD1 mutation did not reveal 
any (likely) pathogenic variants leading to further genetic testing. RetNet-WES analysis in both III.1 and his 
mother II.1 revealed a known variant in the RHO gene, transversion c.404G > C, leading to a missense change 
p.(Arg135Pro). Interestingly, the RHO variant was shown to occur in a mosaic state (variant allele frequency 
(VAF) of ~ 21%) in the mother (II.1) (Fig. 4). This was confirmed by Sanger sequencing. To investigate the muta-
tion load in other tissues than blood in an accurate way, targeted NGS, characterized by a high coverage, was 
performed on DNA from maternal leucocytes, buccal cells and hair follicles (II.1) and revealed a VAF ranging 
from 25.06 to 41.72% in the different tissues, with the highest VAF found in hair follicles and the lowest in the 
patient’s blood (Fig. 5).
The son was shown to be heterozygous for the RHO variant (Fig. 4). Targeted testing showed presence of 
the variant in both affected brothers (III.1 and III.2) and absence in the unaffected sisters (III.3 and III.4). This 
variant is a known RHO missense variant, already previously reported in  ADRP2,15. Classification of the variant 
following ACMG and ACGS criteria revealed this is a likely pathogenic variant (class 4) (Table 1)9–12.
Discussion
We report a family including a female with a suspected X-linked RP carrier-like phenotype, who proved to be 
mosaic for the dominant variant c.404G > C p.(Arg135Pro) in the RHO gene, and her two sons with a classic RP 
phenotype, heterozygous for the same RHO variant.
RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked fashion, depending on the 
gene involved. Analysis of the pedigree can be performed as a first step to discriminate between the different 
modes of inheritance. In ADRP, vertical transmission can be seen. In such families, the patients often display 
a similar disease course and comparable clinical manifestations. However, specific cases of ADRP with vari-
able expressivity and non-penetrance have been described. For example, in PRPF31-associated ADRP, different 
patients from the same family with the same mutation can have a variable disease severity or can be even totally 
 asymptomatic17. In XLRP, affected male individuals usually display a more severe and early-onset phenotype, 
while most female carriers show either RP characteristics later in life or stay  asymptomatic15. In the latter case, 
thorough functional testing with electroretinography, BAF and fundus imaging, will reveal retinal abnormalities.
In the family reported here, BAF imaging in the mother revealed patches of hyper-autofluorescence randomly 
distributed and interspersed by normal areas throughout the retina in both eyes. This is a typical finding in female 
carriers of XLRP, due to X-inactivation18. Interocular asymmetry in the female proband was also a clinical aspect 
Figure 4.  Genomic testing. (Left) Whole exome sequencing reads visualized in the Integrative Genomics 
Viewer (IGV), showing the RHO variant c.404G > C p.(Arg135Pro) in a mosaic state (variant allele frequency 
[VAF] of ~ 21%) in the mother (II.1) (top). Sanger sequencing confirmation of the mosaic variant is shown at the 
bottom. (Right) IGV view of the RHO variant c.404G > C p.(Arg135Pro) in a heterozygous state (VAF: ~ 47%) in 
the son (III.1) (top). Sanger sequencing confirmation of the heterozygous variant is shown at the bottom (III.1).
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Figure 5.  Mosaicism in multiple tissue types. Massively parallel sequencing reads visualized in the Integrative 
Genomics Viewer (IGV), showing the RHO variant c.404G > C p.(Arg135Pro) in a mosaic state in multiple 
tissues. (A) blood sample 1: variant allele frequency (VAF) of 31,97,279%. (B) blood sample 2: VAF of 30,4457%. 
(C) buccal mucosa sample 1: VAF of 40,9042%. (D) buccal mucosa sample 2: VAF of 25,0641%. (E) Sample of 
hair follicle: VAF of 41, 72,123%.
Table 1.  Variant classification using ACMG 2015 and ACGS guidelines. PM, pathogenic moderate; PP, 
pathogenic supporting; PS, pathogenic strong.
Gene RHO
RefSeq transcript ID NM_000539.3
g. notation (HGVS) (GRCh38/hg38) g.129530918G > C
c. notation (HGVS) c.404G > C
p. notation (HGVS) p.(Arg135Pro)
Criteria  >  = 3 moderate pathogenic arguments (PM1, PM2, PM5)
Population data PM2: The variant is NOT present in gnomAD
Genotype and phenotype of the patient PP4_PP: the phenotype of the patient & family history is specific to one monogenic disorder caused by this gene
Literature and databases PP5: variant is pathogenic following reliable sourcesClinVar ID: 18,175,313, variant described in patients with ADRP
Computational predictions
PP3: prediction programs suggest a deleterious effect of the missense variant
PM5: missense variant in a codon in which another pathogenic variant has been found (known 
pathogenic variant: p.(Arg137Ala) and variant p.(Arg137Cys). Pathogenic missense variant: 
c.404G > T p.(Arg135Leu) [transcript NM_000539.3]
Functional data PM1: missense variant is located in mutation hotspot and/or domain in which no benign variants have been reported. * Hot spot/type domain: 7_tm1
Segregation data
PP1: the variant co-segregates with disease in several (additional) affected family members (1–2 
family members). Number of affected family members with the variant: 3 (2 additional). Number 
of unaffected family members without the variant
Allelic data Not applicable
Conclusion CLASS 4 (Likely Pathogenic)
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suggestive of XLRP. Indeed, 9% of 125 females heterozygous for an RPGR mutation show interocular  asymmetry6. 
Given this clinical presentation and the RP phenotype seen in her sons, genetic testing of the XLRP genes was 
conducted. However, no mutation was found. Subsequent RetNet-WES analysis in III.1 and his mother II.1 
identified a variant in the RHO gene c.404G > C p.(Arg135Pro). Interestingly, mosaicism of this variant was 
shown in the mother II.1, estimated to be 21% on DNA from leukocytes, and heterozygosity was shown in her 
affected son III.1. Co-segregation of the variant with the disease was shown.
Genetic mosaicism is characterized by two or more sets of cell lines with different genotypes in the same 
individual, resulting from a postzygotic mutation. A variety of factors, including the biological function of the 
gene, the intrinsic effect of the mutation, the moment when the mutation occurred, and its tissue distribution 
will determine the type of mosaicism and its phenotypic consequences. This was demonstrated by Cao et al. 
who investigated the allelic fraction and clinical effects of 120 clinically relevant mosaic single nucleotide vari-
ants. They showed that an alternate allele fraction (AAF) of 13–24% for mosaic variants in MTOR and PIK3CA 
could lead to Smith-Kingsmore syndrome, Cowden syndrome 5, and/or megalocephaly-capillary malformation-
polymicrogyria syndrome, while a comparable AAF of 16–30% for mosaic variants in CACNA1A was found in 
asymptomatic parents of children affected with epileptic  encephalopathies19,20.
Mosaicism can lead to a wide spectrum of phenotypes, ranging from pigment variations to neurofibroma-
tosis type I and osteogenesis imperfecta type  II21. Additionally, a few cases of mosaicism in eye-related pheno-
types have been reported. In particular, it has been shown that approximately 15% of sporadic retinoblastoma 
cases are caused by postzygotic RB1 mutations, that intrafamilial phenotypic variability in aniridia cases can 
be explained by PAX6  mosaicism22,23. In 2016, the contribution of RHO mutations to ADRP in the Israeli and 
Palestinian populations was studied. Segregation analysis of a specific RP-causing RHO mutation [c.548_638dup 
p.(Ile214Alafs*147)] revealed that the mutation originated from a mosaic individual who did not show any clini-
cal signs of RP. The degree of mosaicism in this individual was 13%24. In contrast, the mosaic individual (II.1) 
studied here, showed a variable mutation load ranging from 21 to 42% in the different tissues tested (Fig. 5). 
Indeed, it has been reported that some pathogenic mosaic variants differ in their abundance depending on 
the tissue, which may be explained partly by differential negative and positive selective pressures in different 
 tissues21,25,26. Moreover, a more accurate quantification of mosaicism, even at a lower degree, is possible using 
deep  NGS27. Individual II.1 had phenotypical signs of sectorial RP and a clearly less severe phenotype than that 
observed in her affected sons. It therefore seems that when a certain threshold of mutation load in the retina is 
met, clinical disease becomes manifest. However, it is not possible to know the exact mutation load in the retina 
and how this would compare with the mutation load in blood cells or other types of cells. While the mutation 
reported by Beryozkin et al. has a predicted loss-of-function effect, with a mutation load expected to be propor-
tional to the amount of gene activity, the mutation identified here is known to have a dominant-negative effect, 
likely resulting in lost gene activity that is presumably higher than the mutation  load11,15,23.
When counselling mosaicism, the recurrence risk can theoretically be between 0 and 50%, depending on 
the mutation load in the gametes. In case of somatic mosaicism, the mutation cannot be transmitted to the next 
generation. In case of germline mosaicism however, a clinically unaffected person can transmit the mutation to 
an offspring. A combination of both somatic and gonadal mosaicism is also possible. Pre-implantation genetic 
testing should therefore be discussed as a reproductive option.
In conclusion, we report two male siblings with typical signs of RP and their mother with clinical charac-
teristics highly suggestive for XLRP. While XLRP testing was negative, WES revealed mosaicism of RHO vari-
ant c.404G > C p.(Arg135Pro) in the mother and heterozygosity of this variant in her affected sons. This study 
emphasizes that mosaicism for a dominant mutation should be considered in families suggestive of XLRP but 
testing negative.
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